Combined albumin-lymphocyte score and skeletal muscle index linked to survival in ovarian cancer surgery patients
This retrospective cohort study involved 347 patients with primary ovarian cancer undergoing primary debulking surgery across multiple medical centers. It assessed the combination of albumin-lymphocyte score (ALS) and skeletal muscle index (SMI), termed CAS grade, as a predictor of overall survival (OS) and recurrence-free survival (RFS). Patients with a lower ALS and higher SMI showed improved OS and RFS, with Grade 1 patients (highest BMI) demonstrating the most favorable survival prognosis and Grade 3 patients the poorest. However, exact numbers for effect sizes, absolute outcomes, p-values, and confidence intervals were not reported, limiting quantitative interpretation.
Safety and tolerability data were not reported in the study, so no conclusions can be drawn about adverse events or discontinuations related to the assessment method. The follow-up duration was also not specified, which may affect the reliability of survival estimates.
Key limitations include the retrospective design, which introduces potential biases and precludes causal claims, and the unclear usefulness of CAS grade for predicting prognosis as stated in the study purpose. The practice relevance suggests CAS grade is a meaningful and independent predictor, but this should be interpreted cautiously due to the observational nature and lack of detailed statistical support. Further prospective research is needed to confirm these associations and establish clinical utility.